Tetrodotoxin

Identification

Name
Tetrodotoxin
Accession Number
DB05232
Type
Small Molecule
Groups
Investigational
Description

An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction. Tetrodotoxin is being investigated by Wex Pharmaceuticals for the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Tectin / Tetrodin
Categories
UNII
3KUM2721U9
CAS number
4368-28-9
Weight
Average: 319.268
Monoisotopic: 319.101564535
Chemical Formula
C11H17N3O8
InChI Key
SLBCPBUVHCASIJ-UFHSVNPDSA-O
InChI
InChI=1S/C11H16N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-19H,1H2,(H3,12,13,14)/q-1/p+1/t2?,3?,4?,5-,6?,7-,9?,10?,11?/m0/s1
IUPAC Name
(11S,13S)-3-amino-5,12,13,14-tetrahydroxy-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradec-3-en-4-ium-9-olate
SMILES
[H][[email protected]]12OC3([O-])OC(C4C(O)[NH+]=C(N)NC4(C1O)[[email protected]@H]3O)C2(O)CO

Pharmacology

Indication

For the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Tetrodotoxin binds to what is known as site 1 of the fast voltage-gated sodium channel. Site 1 is located at the extracellular pore opening of the ion channel. The binding of any molecules to this site will temporarily disable the function of the ion channel. Saxitoxin and several of the conotoxins also bind the same site.

TargetActionsOrganism
USodium channel protein type 1 subunit alphaNot AvailableHuman
USodium channel protein type 2 subunit alphaNot AvailableHuman
USodium channel protein type 3 subunit alphaNot AvailableHuman
USodium channel protein type 8 subunit alphaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Death has occurred within 17 minutes of ingestion.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetrodotoxin.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tetrodotoxin.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetrodotoxin.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tetrodotoxin.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tetrodotoxin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrodotoxin.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrodotoxin.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrodotoxin.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tetrodotoxin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Azaperone.Investigational, Vet Approved
AzelastineTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrodotoxin.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetrodotoxin.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrodotoxin.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrodotoxin.Approved, Investigational
BuprenorphineTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrodotoxin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrodotoxin.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tetrodotoxin.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrodotoxin.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrodotoxin.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tetrodotoxin.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrodotoxin.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrodotoxin.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tetrodotoxin.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrodotoxin.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetrodotoxin.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetrodotoxin.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrodotoxin.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrodotoxin.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetrodotoxin.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tetrodotoxin.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrodotoxin.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrodotoxin.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrodotoxin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetrodotoxin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrodotoxin.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetrodotoxin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrodotoxin.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tetrodotoxin.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetrodotoxin.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrodotoxin.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrodotoxin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrodotoxin.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetrodotoxin.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrodotoxin.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tetrodotoxin.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrodotoxin.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tetrodotoxin.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tetrodotoxin.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetrodotoxin.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrodotoxin.Approved
EthanolTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrodotoxin.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrodotoxin.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetrodotoxin.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrodotoxin.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrodotoxin.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetrodotoxin.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetrodotoxin.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrodotoxin.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrodotoxin.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetrodotoxin.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrodotoxin.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetrodotoxin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrodotoxin.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrodotoxin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tetrodotoxin.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrodotoxin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tetrodotoxin.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tetrodotoxin.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tetrodotoxin.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetrodotoxin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrodotoxin.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tetrodotoxin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrodotoxin.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetrodotoxin.Approved, Investigational
HydrocodoneTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrodotoxin.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tetrodotoxin.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrodotoxin.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrodotoxin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tetrodotoxin.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrodotoxin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrodotoxin.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrodotoxin.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Tetrodotoxin.Approved
LofentanilThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrodotoxin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetrodotoxin.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrodotoxin.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tetrodotoxin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrodotoxin.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrodotoxin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetrodotoxin.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tetrodotoxin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tetrodotoxin.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrodotoxin.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetrodotoxin.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrodotoxin.Approved
MethotrimeprazineTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrodotoxin.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tetrodotoxin.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrodotoxin.Approved
MetyrosineTetrodotoxin may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrodotoxin.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved, Investigational
MirtazapineTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tetrodotoxin.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrodotoxin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrodotoxin.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrodotoxin.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tetrodotoxin.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrodotoxin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetrodotoxin.Approved
OpiumThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Opium.Approved, Illicit
OrphenadrineTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetrodotoxin.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrodotoxin.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrodotoxin.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetrodotoxin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrodotoxin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrodotoxin.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrodotoxin.Approved
ParaldehydeTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrodotoxin.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrodotoxin.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved
PerazineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetrodotoxin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrodotoxin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrodotoxin.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetrodotoxin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pomalidomide.Approved
PramipexoleTetrodotoxin may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrodotoxin.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetrodotoxin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tetrodotoxin.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetrodotoxin.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrodotoxin.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetrodotoxin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetrodotoxin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tetrodotoxin.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrodotoxin.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrodotoxin.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrodotoxin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrodotoxin.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrodotoxin.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetrodotoxin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Romifidine.Vet Approved
RopiniroleTetrodotoxin may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrodotoxin.Approved
RotigotineTetrodotoxin may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tetrodotoxin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrodotoxin.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrodotoxin.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrodotoxin.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetrodotoxin.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sultopride.Experimental
SuvorexantTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptTetrodotoxin may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrodotoxin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetrahydropalmatine.Investigational
ThalidomideTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrodotoxin.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrodotoxin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetrodotoxin.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrodotoxin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrodotoxin.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tetrodotoxin.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrodotoxin.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetrodotoxin.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrodotoxin.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrodotoxin.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetrodotoxin.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tetrodotoxin.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrodotoxin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetrodotoxin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zolazepam.Vet Approved
ZolpidemTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tetrodotoxin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetrodotoxin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11692
PubChem Compound
21733122
PubChem Substance
175426959
ChemSpider
27289077
ChEBI
9506
Wikipedia
Tetrodotoxin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedScreeningHealthy Volunteers1
2TerminatedTreatmentPain / Pain, Neuropathic / Peripheral Neuropathy1
3CompletedTreatmentCancers / Pain2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
pKa8.76MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility117.0 mg/mLALOGPS
logP0.42ALOGPS
logP-4.8ChemAxon
logS-0.5ALOGPS
pKa (Strongest Acidic)10.4ChemAxon
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area194.69 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity86.74 m3·mol-1ChemAxon
Polarizability27.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9781
Blood Brain Barrier-0.6809
Caco-2 permeable-0.6763
P-glycoprotein substrateSubstrate0.5082
P-glycoprotein inhibitor INon-inhibitor0.9376
P-glycoprotein inhibitor IINon-inhibitor0.988
Renal organic cation transporterNon-inhibitor0.9066
CYP450 2C9 substrateNon-substrate0.7925
CYP450 2D6 substrateNon-substrate0.7989
CYP450 3A4 substrateNon-substrate0.5602
CYP450 1A2 substrateNon-inhibitor0.8008
CYP450 2C9 inhibitorNon-inhibitor0.884
CYP450 2D6 inhibitorNon-inhibitor0.908
CYP450 2C19 inhibitorNon-inhibitor0.8374
CYP450 3A4 inhibitorNon-inhibitor0.9834
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9821
Ames testNon AMES toxic0.5547
CarcinogenicityNon-carcinogens0.9196
BiodegradationNot ready biodegradable0.9587
Rat acute toxicity2.5238 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9949
hERG inhibition (predictor II)Non-inhibitor0.8694
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetrodotoxins. These are compounds structurally characterized by the presence of the tetrodotoxin skeleton, which is based on 5,7-(epoxymethanooxy)quinazolin-10-olate moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Tetrodotoxins
Alternative Parents
1,3-dioxanes / Hydropyrimidines / Monosaccharides / Oxanes / Tertiary alcohols / Secondary alcohols / Cyclic alcohols and derivatives / Guanidines / Orthocarboxylic acid derivatives / Propargyl-type 1,3-dipolar organic compounds
show 11 more
Substituents
Tetrodotoxin-skeleton / Meta-dioxane / Hydropyrimidine / 1,4,5,6-tetrahydropyrimidine / Monosaccharide / Oxane / Cyclic alcohol / Tertiary alcohol / Guanidine / Orthocarboxylic acid derivative
show 20 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Alkaloids, Tetrodotoxins (C11692)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN1A
Uniprot ID
P35498
Uniprot Name
Sodium channel protein type 1 subunit alpha
Molecular Weight
228969.49 Da
References
  1. Sage D, Salin P, Alcaraz G, Castets F, Giraud P, Crest M, Mazet B, Clerc N: Na(v)1.7 and Na(v)1.3 are the only tetrodotoxin-sensitive sodium channels expressed by the adult guinea pig enteric nervous system. J Comp Neurol. 2007 Oct 1;504(4):363-78. [PubMed:17663442]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN2A
Uniprot ID
Q99250
Uniprot Name
Sodium channel protein type 2 subunit alpha
Molecular Weight
227972.64 Da
References
  1. Sage D, Salin P, Alcaraz G, Castets F, Giraud P, Crest M, Mazet B, Clerc N: Na(v)1.7 and Na(v)1.3 are the only tetrodotoxin-sensitive sodium channels expressed by the adult guinea pig enteric nervous system. J Comp Neurol. 2007 Oct 1;504(4):363-78. [PubMed:17663442]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN3A
Uniprot ID
Q9NY46
Uniprot Name
Sodium channel protein type 3 subunit alpha
Molecular Weight
226291.905 Da
References
  1. Sage D, Salin P, Alcaraz G, Castets F, Giraud P, Crest M, Mazet B, Clerc N: Na(v)1.7 and Na(v)1.3 are the only tetrodotoxin-sensitive sodium channels expressed by the adult guinea pig enteric nervous system. J Comp Neurol. 2007 Oct 1;504(4):363-78. [PubMed:17663442]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN8A
Uniprot ID
Q9UQD0
Uniprot Name
Sodium channel protein type 8 subunit alpha
Molecular Weight
225278.005 Da
References
  1. Sage D, Salin P, Alcaraz G, Castets F, Giraud P, Crest M, Mazet B, Clerc N: Na(v)1.7 and Na(v)1.3 are the only tetrodotoxin-sensitive sodium channels expressed by the adult guinea pig enteric nervous system. J Comp Neurol. 2007 Oct 1;504(4):363-78. [PubMed:17663442]

Drug created on October 21, 2007 16:24 / Updated on December 01, 2017 15:35